Alligator Bioscience AB: Year-end Report January-December 2020

Continued focus on clinical development.

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- "Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile with only minor drug-related side effects."
Per Norlén, CEO Alligator Bioscience



  • New preclinical comparative data showed that mitazalimab has highly competitive immunostimulatory characteristics.
  • IND approved for forthcoming clinical studies in the US.
  • CTA submitted for launch of the forthcoming Phase II study in pancreatic cancer.


  • Predicted therapeutic range dose levels reached in ongoing Phase I study.
  • Data Review Committee approved start of dosing at 200 mg, corresponding to approximately 3 mg/kg.


  • Alligator Bioscience and Aptevo Therapeutics commenced preparations for start of Phase I.


  • ALLIGATOR-FAB™ antibody library launched.


  • Oversubscribed rights issue generated proceeds of SEK 86 million before transaction costs.


October-December 2020

  • Net sales, SEK 0.0 million (0.0).
  • Operating result, SEK -34.1 million (-59.3).
  • Result for the period, SEK -34.5 million (-59.8).
  • Earnings per share before and after dilution, SEK -0.48 (-0.84).
  • Cash flow for the period, SEK -33.2 million (8.6).
  • Cash and cash equivalents, incl. interest-bearing securities, SEK 103.3 million (249.9).

January-December 2020

  • Net sales, SEK 4.4 million (4.4).
  • Operating result, SEK -144.3 million (-214.5).
  • Result for the period, SEK -143.3 million (-210.1).
  • Earnings per share before and after dilution, SEK -2.01 (-2.94).
  • Cash flow for the period, SEK 9.4 million (-19.6).

During the first quarter, the holdings in corporate bonds and interest funds were divested, which had a positive effect on cash flow.

The full report is attached as PDF available on the company's website:

Conference call/webcast
Alligator will host a conference call today, February 26, 2021, at 2:00 p.m. CEST for investors, analysts and media, where CEO Per Norlén and CFO Marie Svensson will present and comment on the Year-end Report. The conference will be held in English.

The conference call will be broadcast live on the web via the link:

Telephone number for the conference call is:
SE: +46850558358
UK: +443333009266
US: +18335268382

For further information, please contact:
Per Norlén, CEO
Phone: +46 46 540 82 00

Marie Svensson, CFO
Phone: +46 46 540 82 03

The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 a.m. CET on February 26, 2021.

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit

This information was brought to you by Cision,c3296041

The following files are available for download:

Alligator Bioscience AB: Year-end Report January-December 2020

Cision View original content:

SOURCE Alligator Bioscience

Company Codes: Bloomberg:ATORX@SS, ISIN:SE0000767188, RICS:ATORX.ST, Stockholm:ATORX

Back to news